We examined the role of MAPK pathway signaling in the context of intrinsic and acquired CDK4i/6i resistance, in part, due to evidence of possible synergies of combination CDK4i/6i plus MAPK pathway inhibitor treatment in breast cancer and superficial spreading melanomas with either NRAS or BRAF mutations. This evidence concerns the gene BRAF and breast carcinoma.